NEWS

January 13, 2015

 Roche licenses investigational beta-lactamase inhibitor OP0595

 OP0595 targets beta-lactamase enzymes in combination with new or existing beta-lactam antibiotics to enhance their effectiveness in difficult-to-treat bacterial infections

Roche (SIX: R...

Please reload

Featured Posts

Fedora Pharmaceuticals Receives Support from the Government of Canada to Battle Antimicrobial Resistance with Novel Pipeline of Antibiotic Candidates

January 16, 2017

1/3
Please reload

Recent Posts
Please reload

Archive
Please reload

Follow Us
  • Facebook Social Icon
  • Twitter Social Icon
  • Google+ Social Icon

11629 – 105 Avenue, Edmonton, AB T5H 0L9

      info@fedorapharma.com  |   780-757-5401

© 2017 Fedora Pharmaceuticals Inc. 

  • Facebook - Black Circle
  • LinkedIn - Black Circle